Search Results

NovAccess Global Inc. announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance the Company’s immunotherapy platform.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, shared an interview with Dr. Scott Irwin, MD, Ph.D., an eminent Professor of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center.

ABVC BioPharma, Inc. today announced that the Phase 1 Site Initiation Visit (SIV) of ABV-1601 was successfully conducted at Cedars-Sinai Medical Center (CSMC) in West Hollywood, California on March 31, 2023.

CalciMedica Inc. announced the acceptance of an abstract for poster presentation by a collaborator from Cedars-Sinai Medical Center at the upcoming Digestive Disease Week 2024 being held May 18-21 in Washington, DC and virtually.

ABVC Biopharma, Inc. today announced that the Cedars-Sinai Medical Center (CSMC, West Hollywood CA) Institutional Review Board (IRB) has approved their institution joining the Phase I study of ABV-1601 for treating depression in cancer patients.

New research by scientists at the Allen Institute’s Brain and Consciousness group and Cedars-Sinai offers an unprecedented look at how neurons respond to ES.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company has entered into a Master Collaboration Agreement (MCA) with Cedars-Sinai Medical Center.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient’s own “killer” T-cells.